| scholarly article | Q13442814 |
| P50 | author | Robert J. Wilkinson | Q30423489 |
| Marie-Ange Demoitié | Q114445751 | ||
| Mookho Malahleha | Q114726200 | ||
| Dereck R Tait | Q116996640 | ||
| Videlis Nduba | Q116996641 | ||
| Elana Van Brakel | Q116996642 | ||
| German Henostroza | Q116996643 | ||
| Gretta L Blatner | Q116996644 | ||
| Tina Singh | Q116996645 | ||
| Elaine J Akite | Q116996646 | ||
| Anne Bollaerts | Q116996647 | ||
| Helen Ayles | Q42761866 | ||
| Michele Tameris | Q55396247 | ||
| Friedrich Thienemann | Q55523569 | ||
| Olivier Van Der Meeren | Q58870759 | ||
| Aisha Khatoon Azam | Q58870762 | ||
| Mark Hatherill | Q76888530 | ||
| Thomas J Scriba | Q77299176 | ||
| Monde Muyoyeta | Q81746849 | ||
| Paul Gillard | Q91747664 | ||
| Ann M Ginsberg | Q100512400 | ||
| Neil A Martinson | Q105452530 | ||
| Thomas G. Evans | Q110768333 | ||
| Andreas H Diacon | Q114419745 | ||
| P2093 | author name string | James C Innes | |
| Elizabeth Hellström | |||
| P2860 | cites work | Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis | Q28486541 |
| Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial | Q29620144 | ||
| The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis | Q30235074 | ||
| The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling | Q30244104 | ||
| Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. | Q30638583 | ||
| Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa | Q33723554 | ||
| The tuberculin skin test versus QuantiFERON TB Gold® in predicting tuberculosis disease in an adolescent cohort study in South Africa | Q33867491 | ||
| Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein | Q34034191 | ||
| Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. | Q34492873 | ||
| Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults | Q37186951 | ||
| A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults | Q37204894 | ||
| A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults | Q37301506 | ||
| Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines | Q37473293 | ||
| The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs | Q37582822 | ||
| Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials | Q38171263 | ||
| Heterogeneity in tuberculosis. | Q38665662 | ||
| Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. | Q38875343 | ||
| Animal Models of Tuberculosis: An Overview | Q38977799 | ||
| Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial | Q39984692 | ||
| Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study | Q40565756 | ||
| Human dendritic cells presenting adenovirally expressed antigen elicit Mycobacterium tuberculosis--specific CD8+ T cells | Q40704217 | ||
| Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting | Q41162993 | ||
| Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis | Q41860986 | ||
| Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial | Q42211419 | ||
| Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial | Q42683018 | ||
| Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine | Q43179227 | ||
| Comparison of mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection | Q46175365 | ||
| Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa | Q46209425 | ||
| Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein | Q47371281 | ||
| Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. | Q49161794 | ||
| Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial. | Q53826203 | ||
| Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. | Q55617820 | ||
| In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis | Q80576923 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tuberculosis | Q12204 |
| P577 | publication date | 2018-09-25 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Phase 2b Controlled Trial of M72/AS01 Vaccine to Prevent Tuberculosis |
| Q64260919 | A Case for Antibodies as Mechanistic Correlates of Immunity in Tuberculosis |
| Q64069523 | A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates |
| Q91321521 | A new tuberculosis vaccine: breakthrough, challenges, and a call for collaboration |
| Q97644982 | A novel formulation of Mtb72F DNA vaccine for immunization against tuberculosis |
| Q94555050 | A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa |
| Q91311589 | A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults |
| Q90384542 | A systematic approach to simultaneously evaluate safety, immunogenicity, and efficacy of novel tuberculosis vaccination strategies |
| Q89866252 | Adaption of the ex vivo mycobacterial growth inhibition assay for use with murine lung cells |
| Q64080155 | Addressing critical needs in the fight to end tuberculosis with innovative tools and strategies |
| Q92597111 | Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity |
| Q91384550 | Adolescent tuberculosis |
| Q98513693 | Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health |
| Q91562435 | Ag85b/ESAT6-CFP10 adjuvanted with aluminum/poly-IC effectively protects guinea pigs from latent mycobacterium tuberculosis infection |
| Q90988221 | Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study |
| Q64080157 | Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial |
| Q92725408 | Analysis of cellular and soluble profiles in QuantiFERON nonconverters, converters, and reverters in the Gambia |
| Q90401221 | Application of Modeling Approaches to Explore Vaccine Adjuvant Mode-of-Action |
| Q100512382 | Blood RNA signatures predict recent tuberculosis exposure in mice, macaques and humans |
| Q64289721 | Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques |
| Q91558311 | Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines |
| Q92572142 | Building a tuberculosis-free world: The Lancet Commission on tuberculosis |
| Q64937268 | CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial. |
| Q64120774 | CXCR6-Deficiency Improves the Control of Pulmonary and Influenza Infection Independent of T-Lymphocyte Recruitment to the Lungs |
| Q89965652 | Cell-Mediated Immune Responses to in vivo-Expressed and Stage-Specific Mycobacterium tuberculosis Antigens in Latent and Active Tuberculosis Across Different Age Groups |
| Q90129924 | Challenges and controversies in childhood tuberculosis |
| Q89820519 | Clinical Development of New TB Vaccines: Recent Advances and Next Steps |
| Q90560580 | Combining immunoprofiling with machine learning to assess the effects of adjuvant formulation on human vaccine-induced immunity |
| Q62898356 | Contemporary Concise Review 2018: Respiratory infections and tuberculosis |
| Q64375071 | Current trends in tuberculosis vaccine |
| Q97092975 | DNA vaccination with the Mycobacterium marinum MMAR_4110 antigen inhibits reactivation of a latent mycobacterial infection in the adult Zebrafish |
| Q64069762 | Designing tuberculosis vaccine efficacy trials - lessons from recent studies |
| Q100416704 | Disease extent and anti-tubercular treatment response correlates with Mycobacterium tuberculosis-specific CD4 T-cell phenotype regardless of HIV-1 status |
| Q92084132 | Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice |
| Q92241929 | Evaluating vaccination strategies for tuberculosis in endemic and non-endemic settings |
| Q95267770 | Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques |
| Q91675421 | Exacting Edward Jenner's revenge: The quest for a new tuberculosis vaccine |
| Q99609312 | Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections |
| Q64051922 | Harnessing donor unrestricted T-cells for new vaccines against tuberculosis |
| Q94948555 | Homoplastic single nucleotide polymorphisms contributed to phenotypic diversity in Mycobacterium tuberculosis |
| Q64118110 | Immunization of Vγ2Vδ2 T cells programs sustained effector memory responses that control tuberculosis in nonhuman primates |
| Q90265933 | Immunogenicity and Safety of the M72/AS01E Candidate Vaccine Against Tuberculosis: A Meta-Analysis |
| Q92580249 | Infect and Inject: How Mycobacterium tuberculosis Exploits Its Major Virulence-Associated Type VII Secretion System, ESX-1 |
| Q90043675 | Inoculum size and traits of the infecting clinical strain define the protection level against Mycobacterium tuberculosis infection in a rabbit model |
| Q92645553 | Insights and challenges in tuberculosis vaccine development |
| Q90999771 | Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model |
| Q90779193 | Meeting report: Global vaccine and immunization research forum, 2018 |
| Q111441919 | Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20–22 April 2021 |
| Q92199317 | Moving tuberculosis vaccines from theory to practice |
| Q61447731 | Mycobacterial Lipoprotein Z Triggers Efficient Innate and Adaptive Immunity for Protection Against Infection |
| Q89667024 | Mycobacterial virulence: impact on immunogenicity and vaccine research |
| Q92551553 | Need for BCG Vaccination to Prevent TB in High-Incidence Countries and Populations |
| Q93097829 | New hope for tuberculosis vaccines |
| Q91306742 | Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations |
| Q92645576 | Prospects and challenges of a new live tuberculosis vaccine |
| Q91588330 | Quality matters: Redefining child TB care with an emphasis on quality |
| Q64107587 | Research and development of new tuberculosis vaccines: a review |
| Q90131082 | Response to comment on: Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity |
| Q104286463 | Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial |
| Q90147842 | Selection of adjuvants for vaccines targeting specific pathogens |
| Q92282330 | Serological Testing for Mycobacterial Heat Shock Protein Hsp65 Antibody in Health and Diseases |
| Q92056148 | Spotting the old foe-revisiting the case definition for TB |
| Q92611221 | Strategies for ending tuberculosis in the South-East Asian Region: A modelling approach |
| Q90752630 | Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis |
| Q60956136 | T Cell Memory to Vaccination |
| Q92487060 | TIPICO IX: report of the 9th interactive infectious disease workshop on infectious diseases and vaccines |
| Q91969406 | The Diversity Outbred Mouse Population Is an Improved Animal Model of Vaccination against Tuberculosis That Reflects Heterogeneity of Protection |
| Q91837155 | The Many Hosts of Mycobacteria 8 (MHM8): A conference report |
| Q60956638 | The Wonder Years: What Can Primary School Children Teach Us About Immunity to ? |
| Q64243683 | The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases |
| Q92056163 | The way forward for tuberculosis vaccines |
| Q90439703 | Towards new TB vaccines |
| Q92572130 | Tuberculosis |
| Q89724634 | Tuberculosis vaccine development: from classic to clinical candidates |
| Q64098097 | Tuberculosis vaccines: Rising opportunities |
| Q93195877 | Tuberculosis: the story after the Primer |
| Q92639851 | Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review |
| Q90345218 | Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology |
| Q60307189 | Vaccines: An achievement of civilization, a human right, our health insurance for the future |
Search more.